Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
James M G LarkinMototsugu OyaMarcella MartignoniFiona ThistlethwaitePaul NathanMoshe C OrnsteinThomas PowlesKathryn E BeckermannArjun V BalarDavid McDermottSumati GuptaGeorge K PhilipsMichael S GordonHirotsugu UemuraYoshihiko TomitaJing WangElisabete MichelonAlessandra di PietroToni K ChoueiriPublished in: The oncologist (2022)
Five-year follow-up for combination treatment with avelumab plus axitinib in previously untreated patients with aRCC showed long-term clinical activity with no new safety signals, supporting use of this regimen within its approved indication in clinical practice (Clinicaltrials.gov NCT02493751).